TQB2825 vs standard immunotherapy for follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called TQB2825 against standard immunotherapy for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if TQB2825 works better at controlling the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 79 years old
- Diagnosed with follicular lymphoma (grade 1-3a) that is CD20-positive
- Cancer has returned or not responded after at least 2 prior treatments, including one with a CD20 antibody
- At least one measurable tumor on a CT scan
- Good organ function and able to care for yourself (ECOG score 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
This trial tests a new drug called TQB2825, given as a shot under the skin, for people with certain types of blood cancer (B-cell lymphomas) that have come back or stopped responding to previous CD20 antibody treatments. The goal is to see if it is safe and works.
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
This trial tests a new drug called TQB2825 combined with chemotherapy for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least one prior treatment. It aims to see if this combination can help when other treatments haven't worked and stem cell transplant is not an option.
This trial is testing a new drug called TQB2825 given alongside standard chemotherapy (R-CHOP or GemOx) for people with diffuse large B-cell lymphoma (DLBCL) or a related type called grade 3b follicular lymphoma. The goal is to see if adding this new drug is safe and works better than standard treatment alone.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.